Ebixa® in Alzheimer’s disease

In a variety of clinical trials, Ebixa® has proven its efficacy and tolerability in patients with moderate to severe Alzheimer’s disease. Compared to placebo, Ebixa® treatment results in improvements, stabilisation, or less pronounced deterioration in key domains: cognition, daily functioning, behaviour, and global response.

Ebixa® is well tolerated, with placebo-level side effects, in both elderly and younger patients and therefore provides an effective and gentle treatment for patients with moderate to severe AD.

Please refer to your local prescribing information for more specific details about Ebixa® in your country. If you are a patient or carer and have further questions on Ebixa, please ask your physician or pharmacist. As health-care professional, please refer to the specific section of this website.

How it works
Nerve cells in the brain – neurons – communicate with each other via electric signals, but also by using messenger substances, called “neurotransmitters”. One of these substances is glutamate. Glutamate is the most frequently used neurotransmitter in the central nervous system, accounting for approximately 70% of all of its excitatory neurotransmission.

Glutamate is believed to be closely linked to the memory and learning process, by regulating the uptake and level of calcium in the neurons. In AD, glutamate release and uptake are chronically dysfunctional, causing an elevated flow of calcium into the neurons.

Ebixa® is an uncompetitive, moderate affinity, NMDA (N-methyl-D-aspartate) receptor antagonist that binds to the NMDA receptor channel, and regulates the calcium influx into the neurons.

Healthcare professionals

Ebixa® is licensed for the treatment of moderate to severe Alzheimer’s disease. As a healthcare professional, we invite you to explore the following website for further information; www.ebixa.com.